Filter
442
Filtered Results: 442
Text search:
Governments
of
Guinea,
Liberia,
Sierra
Leone
Featured
Recommendations
43
New Publications
220
Language
Document type
No document type
348
Studies & Reports
61
Manuals
9
Guidelines
9
Strategic & Response Plan
8
Situation Updates
3
Fact sheets
2
Training Material
1
Resource Platforms
1
Countries / Regions
Sierra Leone
119
Liberia
111
Guinea
63
Global
28
Africa
25
West and Central Africa
15
Nigeria
11
Senegal
10
Congo, Democratic Republic of
10
Ghana
9
Rwanda
9
Côte d’Ivoire / Ivory Coast
8
Mali
7
Ethiopia
5
Cameroon
5
East and Southern Africa
5
Burkina Faso
4
Togo
4
Uganda
3
India
3
Nepal
3
Chad
3
Kenya
3
Benin
3
Central African Republic
3
Guinea-Bissau
2
Afghanistan
2
Germany
2
Tanzania
2
Gambia
2
South Africa
2
Malawi
2
Mozambique
2
Middle East and North Africa
2
Niger
1
Zimbabwe
1
Pakistan
1
South Sudan
1
Zambia
1
Syria
1
Cambodia
1
Bangladesh
1
Namibia
1
Eswatini/ Swaziland
1
Ecuador
1
Botswana
1
Angola
1
Lesotho
1
Sri Lanka
1
South–East Asia Region
1
Western and Central Europe
1
Russia
1
Mauritius
1
Authors & Publishers
Publication Years
Category
Countries
107
Public Health
25
Women & Child Health
21
Clinical Guidelines
20
Key Resources
18
Capacity Building
4
Pharmacy & Technologies
2
Toolboxes
Ebola
179
Rapid Response
24
COVID-19
23
HIV
22
Mental Health
16
Global Health Education
16
TB
8
Refugee
7
Caregiver
7
NTDs
7
Health Financing Toolbox
7
Disability
6
Planetary Health
6
Polio
4
Conflict
4
Specific Hazards
3
NCDs
3
Natural Hazards
1
Zika
1
AMR
1
Pharmacy
1
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment ... people infected with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
Report of the Joint World Health Organization–Brien Holden Vision Institute Global Scientific Meeting on Myopia | University of New South Wales, Sydney, Australia 16–18 March 2015
A new reportshows that people in some 25 countries are set to face devasting levels of hunger in coming months due to the fallout from the COVID-19 pandemic. While the greatest concentration of need...
CEPI is seeking to raise $3.5 billion to implement CEPI’s next 5-year plan. To mitigate the immediate threat of COVID-19 variants, it is activating key elements of this plan now—and seeking to m...
The State of the World’s Children 2013: Children with Disabilities examines the barriers – from inaccessible buildings to dismissive attitudes, from invisibility in official statistics to vicious discrimination – that deprive children with dis...
Atlas of African Health Statistics 2022: Health situation analysis of the WHO African Region
Since 2019, we have been implementing Phase 2 of the ...
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
State of Health in the WHO African Region
recommended
This report is not a country scorecard. Rather, its purpose is to act as a compass to guide progress towards health in the SDGs.
There has been a significant improvement in the state of health in the region with healthy life expectancy - time spen...
Universal health coverage and the Sustainable Development Goals in the WHO African Region
Infection prevention and control measures for Ebola virus disease
The epidemiology of the disease is mediated by the interaction of the parasite (trypanosome) with the vectors (tsetse flies), as well as with the human and animal hosts within a particular environme...
Since 2000, concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important ...
It is too early to know the full impact of COVID-19 on Africa. To date the experience has been varied. There are causes for concern, but also reasons for hope. Early estimates were pessimistic regarding the pandemic’s impact on the continent. But ...
The Strategic Plan of Action and Budget 2016-2025 for the elimination of onchocerciasisin countries was prepared based on the above dlrective for the consideration ... IAF 18.The vision of the plan of action is to eliminate onchocerciasis in 80 percent of Africancountries. Implementation of the plan will also help strengthen health systems at community level while implementing CDI wlll help scale-up interventions agalnst other NTDs to the benefit of the wider national health systems.
